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Carlo Plan (SMCP) [2]. The inverse treatment planning process starts 
with the definition of the SSD, the gantry angle and the collimator 
rotation for each electron field. Then the DAO is initiated and a 
potential aperture or energy change is determined. A cost function 
(cf) which determines the squared dose differences in all voxels of the 
PTV and the OARs between the actual value and a given upper or 
lower limit is to be minimized. The actual dose distribution has to be 
determined efficiently in each iteration step. For this purpose, the 
initial electron field has been divided into a grid of beamlets for 
which the dose distribution has been pre-calculated using eMC [3]. 
Hence, the update of the dose distribution is realized by adding or 
subtracting the corresponding beamlet dose distributions. After DAO 
the final apertures have been set up as MLC shaped fields. To correct 
for the MLC impact on the dose distribution which has not been 
accounted for during the DAO, post processing steps are carried out by 
a weight optimization or adjusting the MLC apertures. The DAO 
implementation has been tested using a water phantom containing an 
artificial PTV and a distal OAR.  
Results: The DAO converged after about 2000 iterative steps which 
corresponds to 25 minutes. In about 15% of the steps, the changes 
selected by the SA have been accepted. The resulting treatment plan 
for the water phantom consists of three fields employing 20 MeV,12 
MeV and 9 MeV. Applying these MLC shaped fields and carrying out the 
post processing weight optimization, this results in a conformal dose 
distribution with a V95 of 92% and a V105 of 11% for the PTV. 
Conclusions: The presented DAO has been successfully implemented 
within SMCP and allows inverse treatment planning of MERT for 
phantom situations. This work was supported by Varian Medical 
Systems. 
References: 
1. D. Henzen et al “Efficient Monte Carlo based Electron Beam Model 
for MERT using a Photon MLC”, ICTR-PHE 2012, Geneva 
2. M.K. Fix et al “An efficient framework for photon Monte Carlo 
treatment planning”, Phys. Med. Biol. 52 (2007) N425-N437, 2009 
3. H. Neuenschwander and E.J. Born “A macro Monte Carlo Method for 
electron beam dose calculations”, Phys Med Biol 37, 107-25 (1992). 
   
PD-0282   
Flattening filter free (FFF) HybridArc for stereotactic treatments in 
the brain 
D. Schmidhalter1, M. Malthaner1, E.J. Born1, A. Pica1, D.M. Aebersold1, 
M.K. Fix1, P. Manser1 
1Inselspital Bern University Hospital and University of Bern, Division 
of Medical Radiation Physics and Department of Radiation Oncology, 
Berne, Switzerland  
 
Purpose/Objective: HybridArc is a new treatment technique available 
in version 4.5 of the treatment planning system iPlan (BrainLAB AG, 
Feldkirchen, Germany). Modulated arc fields are combined with IMRT 
fields along these arcs. The aim of this work was to investigate the 
suitability of HybridArc using the linear accelerator in the flattening 
filter free (FFF) mode for stereotactic treatments in the cranial region 
and to compare this method with HybridArc using the conventional 
flattening filter (FF) mode. 
Materials and Methods: HybridArc was commissioned in iPlan for the 6 
MV FFF as well as for the 6 MV FF mode of a Truebeam equipped with 
a high definition multileaf collimator (Varian Medical Systems, Inc., 
Palo Alto, USA). For 10 patients with single metastases with a median 
target volume of 0.755 ccm (ranging from 0.275 ccm to 4.588 ccm) 
FFF-HybridArc plans were calculated and compared with FF-HybridArc 
plans. Each plan consists of three HybridArc fields with two embedded 
IMRT fields per arc. The dose distributions were analyzed and 
compared according to homogeneity (homogeneity index: H-index = 
(D2% - D98%) / DPrescription * 100%) and conformity (conformity index: CI = 
prescription isodose volume / target volume) to the target. A normal 
tissue structure was defined as the 5 mm wall around the target 
volume. The dose to this normal tissue structure as well as the total 
number of monitor units (MUs) per plan were investigated. 
Results: The mean (mean ± 1 std) H-index over all 10 patients 
decreased from 4.0%±0.4% for the FF-HybridArc method to 2.2%±0.3% 
for the FFF-HybridArc method. The mean conformity index over all 10 
patients was comparable for both methods: 1.35±0.12 and 1.33±0.14 
for the FF-HybridArc and FFF-HybridArc method, respectively. The 
number of MUs per plan decreased by 9% comparing FFF-HybridArc 
plans with FF-HybridArc plans. The maximum and the mean dose in 
the normal tissue structure were decreased by up to 3% when using 
FFF-HybridArc instead of FF-HybridArc. 
Conclusions: FFF-HybridArc is a suitable method for stereotactic 
treatments of small targets in the cranial region (e.g. for brain 
metastases). In comparison to the conventional FF-HybridArc method 
the dose homogeneity in the target volume is improved while the 
conformity remains the same. The total number of MUs is decreased 
and the normal tissue sparing is slightly improved. Additionally, the 
higher dose rates available using FFF modes in comparison to FF 
modes leads to shorter beam on times.  
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Purpose/Objective: In conventional radiotherapy of locally advanced 
lung cancer (LALC) doses levels are homogeneously delivered to the 
entire PTV, whereat dose escalation is restricted by normal tissue 
toxicity. Several studies have shown the geometrical correlation 
between high FDG uptake in a PET scan and tumour recurrence. This 
is the rationale for FDG-based local dose escalation, e.g. by dose 
prescription on the voxel values of a PET scan – dose painting by 
numbers (DPBN). The aim of this study is to investigate the robustness 
of the DPBN plans against tumour motion.  
Materials and Methods: For 3 patients with LALC respiratory-
correlated 4D-PET/CT studies were acquired (Philips GeminiTF64). 
The GTV delineation of the primary tumour was performed manually 
on 3DCT and a 10mm margin was used for generation of the PTV. 
DPBN plans were generated with a baseline dose of 60Gy at 2Gy 
fractions to the entire PTV and a DPBN boost to the GTV. A linear 
relationship between the prescription dose to voxels within the GTV 
and the underlying SUV in ungated PET reconstruction was used. 
Planning was performed with Pinnacle TPS, research version 9.100 
(Philips, USA) using a plugin extension for DPBN that was created by 
the authors. In the IMRT planning optimization, doses within GTV were 
increased up to a maximum dose of 100Gy in 30 fractions, applying 
the standard normal tissue constraints from the clinical routine. A 
DPBN plan was created and the dose distributions were transformed to 
and summated in asingle CT phase using a model-based nonrigid image 
registration. The 3D and summated 4D DPBN plans were compared 
based on DVHs of the target volumes and volumes corresponding to 
50-90% of SUVmax. 
Results: Summated 4D plans showed significant differences in the 
doses to the target volumes with maximal differences up to 7% in the 
Dnear-min and Dnear-max as compared to the 3D DPBN plans. The 
high-dose region stayed confined to the GTV in summated 4D plans. In 
mean, in all summated 4D plans, the dose delivered to 99% of the 50% 
and 90% of SUVmax volumes exceeded 72Gy and 83Gy respectively, 
compared to 76Gy and 87Gy in 3D plans. The dose to the lung and 
other organs at risk didn't differ significantly within 3D and summated 
4D plans.  
Conclusions: Our first results show good target coverage and no hot 
spots outside of PTV for DPBN plans. Further evaluation of 4D 
accumulation of DPBN plans for other patients with locally advanced 
lung cancer is in progress. 
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The preparation and delivery of high quality radiotherapy is 
dependent on a healthy working relationship between the members of 
the multidisciplinary team.   Recognition of the knowledge and skills 
sets of each profession and how they can complement those of our 
colleagues is both positive and enriching for professionals and 
improves the care given to our patients.  The problem of professional 
recognition and lack of dedicated education programmes faced by 
radiotherapy physicists in many countries is similar to those faced by 
the RTTs and if we worked together to address these in the context of 
improved patient care our voices may have a far greater impact.    
The experience over the past years in ESTRO has clearly demonstrated 
the benefits of such collaboration and the level of mutual respect 
shown by the two groups has resulted in shared conferences and 
workshops becoming much more the norm.   My personal experience 
with my physics colleagues has been challenging and exciting and I 
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have benefitted greatly from these interactions.   Results of our 
collaboration can be seen in the ROSIS project and associated short 
courses, involvement in clinical audit as members of the 
multidisciplinary team and several joint publications.  It is a great 
honour to receive this award and I am delighted to ‘finally’ be a 
physicist albeit it an honorary one – but maybe that is even better! 
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Purpose/Objective: Radiotherapy of several major tumour sites 
involves simultaneous treatment of multiple targets, typically 
occurring when irradiation of both the primary and elective targets is 
indicated. In the treatment of locally advanced prostate cancer, the 
dominating residual geometrical uncertainties following image-
guidance can be ascribed to deformations and uncorrelated motion of 
the involved targets: the prostate (CTV-p), the seminal vesicles (CTV-
sv) and the pelvic lymph nodes (CTV-ln). The aim of this study was to 
use a statistical deformation motion model to simulate target motion 
throughout a course of treatment in this clinical scenario, for the 
purpose of margin evaluations. 
Materials and Methods: The study was based on target delineations 
for 19 patients, all with a CT-set consisting of one planning and 9-10 
repeat CTs. After rigidly aligning the repeat CTs to the planning CT 
based on intra-prostatic markers, the displacement vectors between 
the target shapes in the planning CT and those in the repeat CTs were 
calculated with deformable registration. For each patient, a motion 
model based on principal component analysis (PCA) of these 
displacement vectors was created. From this model statistical 
meaningful inter- and extrapolations of the delineated target shapes 
were made to construct new target shapes according to their 
probabilities of occurrence and without prior assumptions of the 
relative importance of the different motion and deformation patterns. 
Maximally conformal synthetic dose distributions were created for 
various uniform CTV-to-PTV expansions in the planning CT. For each 
patient, the motion model was employed to analyse target coverage 
distributions for 1000 simulated treatment courses on each of these 
synthetic dose distributions. 
Results: Simulations of inter-fractional motion resulted in 7,10 and 18 
patients with an estimated average accumulated dose of at least 95% 
of the prescribed dose to 99% of the CTV (D99), for uniform margins 
around the prostate of 3mm, 4mm and 5mm, respectively. For the 
seminal vesicles and the pelvic lymph nodes, margin expansion of 
3mm, 5mm, 7mm, 9mm resulted in 1, 11, 15, 16 and 8, 18, 18, 18 
patients respectively with an expected average D99> 95% of the 
prescription. In Figure 1, the estimated average D99 including the10%-
90%-percentiles for each target are shown. 
 
 
Conclusions: We have developed a deformable registration based 
motion simulation model and successfully applied this on a 
comprehensive repeat CT data-set. For the patients included in this 
study, 90% had full target coverage with CTV-to-PTV expansions of 
5mm for the prostate, 11mm for the seminal vesicles and 5mm for the 
pelvic lymph nodes.  
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Purpose/Objective: Respiratory motion introduces complex spatio-
temporal variations in the dosimetry of radiotherapy and may 
contribute to uncertainties in radiotherapy planning. This novel in 
vitro study investigates the potential radiobiological implications 
occurring due to tumour motion in lung cancer radiotherapy. 
Materials and Methods: A bespoke phantom and motor-driven 
platform to replicate respiratory motion and study the consequences 
on tumour cell survival in vitro was constructed. Human non-small cell 
lung cancer cell lines (H460 and H1299) were irradiated in uniform (0-
8Gy) and modulated radiotherapy fields (4Gy) in the presence and 
absence of respiratory motion (14 and 21 respirations/minute). 
Clonogenic survival was calculated for irradiated and shielded regions. 
Direction of motion, replication of dosimetry by MLC manipulation and 
oscillating lead shielding were investigated to confirm differences. 
Differences were compared using the Mann-Whitney test. 
Results: No difference in survival was seen for cell lines uniformly 
irradiated with or without motion. With respiratory motion survival 
was significantly higher for out-of-field regions for H460 and H1299 
compared with static irradiation of 50% of the flask (p<0.0005). 
Significantly higher survival was found in the in-field region for the 
H460 cell line (p<0.03). Oscillating lead shielding also produced these 
significant differences. MLC and perpendicular motion had no 
significant difference compared to static irradiations. 
Conclusions: These data indicate that respiratory motion can impact 
on in- and out-of-field survival in the presence of non-uniform 
irradiation for lung cancer cell lines. This may have implications for 
the efficacy of radiotherapy particularly in areas where tumour is 
missed due to respiratory motion. 
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